United Therapeutics (UTHR) Tops Q2 EPS by 133c

This morning United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.55, $1.33 better than the analyst estimate of $3.22. Revenue for the quarter came in at $412.6 million versus the consensus estimate of $395.15 million.

"We are pleased with our second quarter 2016 financial results as total revenues exceeded $400 million and earnings beat $200 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "These financial results strengthen our ability to advance our late-stage pipeline programs in cardiopulmonary disease and oncology, as well as early-stage programs in multiple indications."

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

You May Also Be Interested In

• Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
• 8x8, Inc. (EGHT) Reports In-Line Q2 EPS
• Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance